Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Philip J. ferrone, M.D., Long Island Vitreoretinal Consultants
ClinicalTrials.gov Identifier:
NCT00440609
First received: February 23, 2007
Last updated: August 1, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2012
  Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)